Last reviewed · How we verify

NCT05112757

Effective Conversion of Individuals at Risk

Terminated NA Last updated 12 December 2022
What this trial tests

NA trial testing Smartphone application use in Obstructive Sleep Apnea in 77 participants. Terminated before completion.

Timeline
24 February 2022
Primary endpoint
8 December 2022
8 December 2022

Quick facts

Lead sponsorPhilips Electronics Nederland B.V. acting through Philips CTO organization
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment77
Start date24 February 2022
Primary completion8 December 2022
Estimated completion8 December 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Philips Electronics Nederland B.V. acting through Philips CTO organization

Who can join

18 and older, any sex, with Obstructive Sleep Apnea or Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to guide participants in recognizing their OSA (obstructive sleep apnea) and AFib (atrial fibrillation) symptoms, realizing what medical conditions can cause these symptoms (if any) and inform the participants on their possible diagnosis

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Obstructive Sleep Apnea

Currently open trials in the same condition.

Other Philips Electronics Nederland B.V. acting through Philips CTO organization trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05112757.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing